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Hallmarks of the inflammatory process in Type I diabetes are
macrophage activation, local release of β-cell-toxic cytokines
and infiltration of cytotoxic T lymphocytes. We have observed
recently that mice overexpressing active FRK (fyn-related
kinase)/RAK (previously named GTK/Bsk/IYK, where GTK
stands for gut tyrosine kinase, Bsk for β-cell Src-homology kinase
and IYK for intestinal tyrosine kinase) in β-cells exhibit increased
susceptibility to β-cell-toxic events, and therefore, we now at-
tempt to find a more precise role for FRK/RAK in these pro-
cesses. Phosphopeptide mapping of baculovirus-produced mouse
FRK/RAK revealed an autophosphorylation pattern compatible
with Tyr-394 being the main site. No evidence for in vitro
phosphorylation of the C-terminal regulatory sites Tyr-497 and
Tyr-504 was obtained, nor was there any indication of in vitro
regulation of FRK/RAK kinase activity. Screening a panel of
known tyrosine kinase inhibitors for their ability to inhibit
FRK/RAK revealed several compounds that inhibited FRK/RAK,
with a potency similar to that reported for their ability to
inhibit other tyrosine kinases. Cytokine-induced islet toxicity was
reduced in islets isolated from FRK/RAK knockout mice and
this occurred without effects on the production of nitric oxide.
Addition of the nitric oxide inhibitor nitroarginine to FRK/RAK
knockout islets exposed to cytokines decreased cell death to a
basal level. In normal islets, cytokine-induced cell death was
inhibited by the addition of two FRK/RAK inhibitors, SU4984
and D-65495, or by transfection with short interfering RNA
against FRK/RAK. It is concluded that FRK/RAK contributes
to cytokine-induced β-cell death, and inhibition of this kinase
could provide means to suppress β-cell destruction in Type I
diabetes.
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INTRODUCTION
The β-cell-destructive processes in Type I diabetes are not
completely understood, but are supposed to involve multiple
pathways [1]. At an early stage, tissue macrophages become
activated in the vicinity of the islets, producing β-cell-cytotoxic
cytokines such as IL-1β (interleukin-1β), tumour necrosis factor
α and IFN-γ [2]. This process is supposed to induce partial β-cell
damage [3,4]. Subsequent to this, cytotoxic T-cells are recruited
to the site of inflammation and these eventually kill most of the
remaining β-cells [5].
FRK (fyn-related kinase)/RAK (also named GTK/Bsk/IYK,
where GTK stands for gut tyrosine kinase, Bsk for β-cell Src-
homology kinase and IYK for intestinal tyrosine kinase) is a
cytoplasmic tyrosine kinase belonging to the SRC family [6,7].
FRK/RAK is expressed in liver, lung, kidney, mammary-gland
epithelium, intestine and the pancreas including islets [8,9].
Previous studies have suggested Tyr-497 and Tyr-504 in the
C-terminus as potential regulators of kinase activity [10,11]. A
transgenic mouse with active FRK/RAK expressed in β-cells
under the control of the insulin promoter exhibits not only an
increased β-cell mass, but also demonstrates enhanced suscepti-
bility to the β-cell toxin streptozotocin and to the cytokines IL-
1β and IFN-γ [12]. When such mice were subjected to partial
pancreatectomy, they displayed a compensatory increase in β-cell
replication [13]. The combined results suggest the dual role of
FRK/RAK for β-cell function: increased cell replication and
increased β-cell death under conditions of imposed toxicity.
To address further the role of FRK/RAK for the destruction
of β-cells in response to cytotoxic cytokines, we first decided
to characterize the kinase properties of mouse FRK/RAK.
Furthermore, we addressed the role of the kinase in the β-cell-
cytotoxic process after cytokine exposure by studies on islets
isolated from FRK/RAK knockout mice. Finally, we investigated
islet death in the presence of FRK/RAK inhibitors. The results
suggest a role for FRK/RAK in the β-cell-destructive process in
response to cytotoxic cytokines.
MATERIALS AND METHODS
Materials
Sf9 insect cells, pVL1393 and the Baculovirus Expression Vector
System kit were obtained from PharMingen (San Diego, CA,
U.S.A.); fetal calf serum and penicillin/streptomycin were from
HyClone Europe (Cramlington, Northumberland, U.K.); Grace’s
insect medium, sodium orthovanadate, PMSF, dithiothreitol,
Nonidet P40 and leupeptin were from Sigma (St. Louis, MO,
U.S.A.), trypsin (modified sequencing grade) was from Promega
(Madison, WI, U.S.A.), Protein A–Sepharose CL-4B and [γ -
32P]ATP (3000 Ci/mmol) were from Amersham Biosciences
(Uppsala, Sweden) and TC lactalbumin hydrolysate and TC
Abbreviations used: Bsk, β-cell Src-homology kinase; FRK, fyn-related kinase; GTK, gut tyrosine kinase; IFN-γ, interferon γ; IL-1β, interleukin-1β; IYK,
intestinal tyrosine kinase; PDGFR, platelet-derived growth factor receptor; PP2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine; RNAi,
RNA interference; SHB, SH2 protein in β-cells; siRNA, short interfering RNA.
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yeastolate were from Difco Laboratories (Detroit, MI, U.S.A.).
All kinase inhibitors except D-65495, D-68129 and AG1295 were
obtained from Calbiochem (La Jolla, CA, U.S.A.). D-65495
and D-68129 [14] (compounds 53 and 67) and AG1295 were
generously provided by Dr Frank Böhmer (Jena University, Jena,
Germany). Specific siRNA (short interfering RNA) for FRK/
RAK, scrambled oligonucleotide and Fluorescein-Luciferase
GL2 duplex were obtained from Dharmacon Research (LaFayette,
CO, U.S.A.). All other reagents were from Merck (Darmstadt,
Germany).
Cell culture and transfection
Sf9 insect cells were kept in culture in Grace’s insect medium sup-
plemented with lactalbumin hydrolysate (1.67 g/500 ml), yeasto-
leate (1.67 g/500 ml), benzylpenicillin (100 units/ml), strepto-
mycin (0.1 mg/ml) and 10 % fetal calf serum at 27 ◦C in culture
flasks. Full-length wild-type FRK/RAK cDNA or FRK/RAK
cDNAs containing a Y497F (Tyr497→Phe) or Y504F single
mutation or a Y497/504F double mutation [10] were subcloned
into a pVL1393 baculovirus transfer vector. All mutations were
verified by DNA sequencing. The construct was transfected into
Sf9 cells using a Baculovirus Expression System Vector System
kit according to the manufacturer’s instructions. The conditioned
medium containing baculovirus particles expressing FRK/RAK
cDNA was used for amplification to obtain high-virus titres. The
expression of FRK/RAK in Sf9 cells after infection with high-
virus titre was confirmed by SDS/PAGE, followed by Western-
blot analysis using FRK/RAK antiserum [10] as a probe. Sf9 cells
(107) were infected with high-virus titre-conditioned medium for
3 days before phosphorylation experiments.
In vitro phosphorylation
Sf9 cells expressing wild-type or mutated FRK/RAK cDNA were
harvested and lysed in RIPA buffer (150 mM NaCl, 30 mM
Tris, pH 7.5, 10 mM EDTA, 1 % Nonidet P40, 0.5 % sodium
deoxycholate and 0.1 % SDS), supplemented with protease
inhibitors (2 mM PMSF, 0.05 mM leupeptin and 1 % Trasylol)
and 0.1 mM sodium orthovanadate. Nuclei were removed by
centrifugation and the cell extract was immunoprecipitated with
FRK/RAK antiserum [10] and immobilized on Protein A–
Sepharose CL-4B. The phosphorylation reaction was performed
in kinase buffer (40 mM Hepes, pH 7.5, 10 mM MgCl2, 3 mM
MnCl2 and 10 % glycerol), supplemented with 0.1 µM [γ -32P]-
ATP, 0.1 mM sodium orthovanadate and 1 mM dithiothreitol for
15 min at room temperature, and the samples were subsequently
subjected to phosphopeptide mapping. In some experiments,
an FRK/RAK substrate peptide was included during the phos-
phorylation reaction, and substrate phosphorylation was deter-
mined at different concentrations of the peptide as described
in [11].
Phosphopeptide mapping
Phosphopeptide mapping was performed as described in [15].
Briefly, the phosphorylated proteins were subjected to SDS/PAGE
(7.5% gel), blotted on to Immobilon filters and exposed to
Hyperfilm for 45 min at room temperature. Radioactive proteins
of 58 kDa were excised from the filter and subjected to tryptic
degradation [16]. The tryptic fragments were dissolved in a pH 1.9
buffer (formic acid/acetic acid/double-distilled water, 23:78:899)
and applied on 0.1 mm cellulose TLC plates (Merck). First-
dimension thin-layer electrophoresis was performed in the pH 1.9
buffer at 2000 V for 40 min using a Hunter thin-layer electro-
phoresis apparatus (HTLE-7000; CBS Scientific, Del Mar, CA,
U.S.A.). Second-dimension ascending chromatography was run
in isobutyric acid buffer (isobutyric acid/n-butyl alcohol/pyridine/
acetic acid/double-distilled water, 625:19:48:29:279) for 12 h
at room temperature. After exposure for 1 week to Hyperfilm at
−70 ◦C or on a Bio-Imaging Analyzer screen (Fuji, Tokyo,
Japan), spots corresponding to radioactive phosphopeptides were
scraped from the plates, eluted in the pH 1.9 buffer and freeze-
dried, and subsequently subjected to Edman degradation and two-
dimensional phosphoamino acid analysis.
Kinase inhibitor experiments
Wild-type FRK/RAK produced in Sf9 cells was immunoprecipit-
ated and subjected to in vitro kinase reactions as above, including
the addition of different concentrations of the inhibitor. FRK/RAK
autophosphorylation was determined and normalized for the
amount of FRK/RAK present in the immunoprecipitates by
Western-blot analysis. Approximate IC50 values were determined
based on the profile of inhibition for each inhibitor. For inhibitors
that displayed inhibitory effects, experiments were repeated
2–3 times.
FRK/RAK knockout mice
FRK/RAK knockout mice [17] were bred on the C57BL/KS strain
of mice. After 3–4 generations of breeding, FRK/RAK −/− or
+/+ littermates were used for experimentation.
Islet cell viability test, insulin secretion and NO
(nitric oxide) production
Islets were isolated from either NMRI (Naval Marine Research
Institute) mice or FRK/RAK +/+ or −/− mice on a mainly
C57BLKS background by collagenase isolation. The islets were
then cultured in RPMI 1640 containing 11 mM glucose, 10%
fetal bovine serum and antibiotics for 3–7 days. The islets were
then subjected (or not) to cytokine exposure for 18 h before
insulin secretion experiments, NO determination or islet viability.
In some experiments, tyrosine kinase inhibitors were added
10 min before the cytokines. Islet cell viability was determined
by propidium iodide and Hoechst 33342 staining [18]. Insulin
secretion, insulin content and NO were measured as described in
[12].
FRK/RAK RNAi (RNA interference)
Freshly isolated islets or RIN-Y504F cells [11] were transfected
by the LIPOFECTAMINETM method with siRNA against FRK/RAK
using either a double-stranded DNA/RNA oligonucleotide cor-
responding to the sequence AAGCGACTGGGATCTGGTCA-
GTT (nt 1217–1239 of the mouse FRK/RAK mRNA; the sense
oligonucleotide GCGACUGGGAUCUGGUCAGdTdT and the
antisense oligonucleotide CUGACCAGAUCCCAGUCGCdTdT)
or a scrambled siRNA oligonucleotide (CAGUCGCGUUUG-
CGACUGG), which in some experiments was fluorescently
labelled (Fluorescein-Luciferase GL2 duplex). The oligonuc-
leotides had been converted into their 2′-hydroxyl form, annealed,
purified and desalted. The transfection mixture contained 5 µl of
LIPOFECTAMINETM and 0.84 µg of oligonucleotide in 0.2 ml
of Opti-MEM, which had been preincubated for 20 min at room
temperature. This mixture was then added to serum-free islets
or RINm5F cells. After 3 h in Opti-MEM, RPMI 1640 medium
containing serum was added, which was changed after 24 h when
cytokines were added as above. Alternatively, islet transfection
efficiency was evaluated at that point after trypsinization and
FACS analysis (Becton–Dickinson, San Diego, CA, U.S.A.). Cell
c© 2004 Biochemical Society
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Figure 1 Tryptic peptide fragments of baculovirus-produced FRK/RAK autophosphorylation sites
Wild-type (A, E), Y504F (B), Y497F (C) and Y497/504F (D) murine FRK/RAK is shown. In (F), the phosphopeptide map of in vitro phosphorylated VDNEDIYESKHEIKKK peptide is shown, of which
one position is identical with that of the wild-type FRK/RAK pattern. (E) is identical with (A), except that the experiment was performed at a different time.
viability was determined by staining with propidium iodide after
an additional 18 h, and FRK/RAK protein expression in the RIN-
Y504F cells was determined by Western-blot analysis.
RESULTS
Phosphopeptide analysis of FRK/RAK autokinase activity
To investigate the properties of the FRK/RAK kinase, the protein
and its Y497F, Y504F and Y497/504F mutants were expressed
in Sf9 insect cells after baculovirus infection. Figure 1 shows the
phosphopeptide map of FRK/RAK autokinase activity. The main
spot was a charged peptide, which was seen in both the wild-type
and the FRK/RAK mutants (Figures 1A–1D). Edman degradation
of radioactive material in this spot after elution (Figure 2A)
revealed radioactivity at position 7, which corresponds to two po-
tential trypsin fragments containing tyrosine residue at position 7,
Tyr-324 and Tyr-394. Tyr-416 in SRC has been established as
the main autophosphorylation site [19]. On the basis of the
structural resemblance between SRC and FRK/RAK, Tyr-394 is
the FRK/RAK homologue to Tyr-416 in SRC. Thus our results
are compatible with the view that the main autophosphorylation
site in FRK/RAK is Tyr-394, sharing this feature with SRC.
In addition, mutation of Tyr-394 to phenylalanine resulted in
c© 2004 Biochemical Society
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Figure 2 In vitro characterization of FRK/RAK kinase
(A) Edman degradation of the main autophosphorylation site (indicated with an arrow in Fig-
ure 1). The radioactive counts in each cycle are shown. Two tryptic fragments of murine FRK/RAK
with tyrosine residue at position 7 are anticipated. (B) Kinase activity of baculovirus-produced
wild-type and mutant FRK/RAK. A synthetic peptide was used as a substrate. Peptide
phosphorylation values are given in dpm (disintegrations/min) after normalization for the
amount of FRK/RAK kinase present in each reaction. Results are the means +− S.E.M. for four
independent measurements.
decreased FRK/RAK kinase activity when expressed in RINm5F
cells [20].
To verify that the main autophosphorylation site is one derived
from the Tyr-394 trypsin-cleavage fragment, in vitro phosphoryl-
ation of the VDNEDIYESKHEIKKK peptide (corresponding to
the sequence encompassing Tyr-394 in FRK/RAK) using baculo-
virus-produced FRK/RAK was performed. Phosphopeptide
mapping of this in vitro phosphorylated peptide (Figures 1E and
1F) revealed several spots, which is compatible with the view
that partial cleavage of the numerous lysine residues present
in the peptide occurred. One of these spots was identical with the
spot identified as the main FRK/RAK autophosphorylation site.
This lends further support to the notion that the main autophos-
phorylation site in FRK/RAK is Tyr-394.
The FRK/RAK mutants displayed an identical phosphopeptide
map (Figure 1) as the wild-type FRK/RAK, indicating that,
in vitro, the kinase does not autophosphorylate the putative regu-
latory tyrosine residues in its C-terminus.
In vitro kinase activity of baculovirus-produced mutant or
wild-type FRK/RAK was determined using a peptide substrate
corresponding to the Tyr-394 site. Similar rates of activity
Figure 3 Islet cell death in FRK/RAK control (+/+) or knockout (−/−) islets
after exposure to IL-1β (75 units/ml) + IFN-γ (1500 units/ml) for 18 h
In two groups, the NO inhibitor nitroarginine (2 mM) was added. Results are the means +− S.E.M.
for six independent measurements.
were observed in the wild-type, Y497F and Y504F mutants,
whereas the Y497/504F double mutant displayed somewhat lower
activity (Figure 2B). This is in contrast with what was observed
with FRK/RAK expressed in NIH3T3 cells [10] and RINm5F
cells [11,20] and probably reflects the absence of regulatory
phosphorylation of the C-terminal residues from baculovirus-
produced FRK/RAK.
Cytokine-induced islet cell toxicity in FRK/RAK knockout islets
To assess directly the participation of FRK/RAK in cytokine-
induced β-cell toxicity, islets were isolated from FRK/RAK
−/− knockout mice or +/+ littermates. Islet cell viability after
exposure to 75 units/ml IL-1β plus 1500 units/ml IFN-γ for 18 h
is shown in Figure 3. Islet cell death was significantly reduced after
cytokine exposure in the exposed −/− islets compared with the
+/+ littermate controls. The subsequent addition of an inhibitor
of NO formation, 2 mM nitroarginine, significantly reduced islet
cell death. However, the difference between FRK/RAK +/+ and
−/− islets remained, i.e. the latter exhibited a level of islet cell
death in the combined presence of nitroarginine and cytokines
that was similar to that of the islets not exposed to cytokines (Fig-
ure 3). Thus the results suggest that FRK/RAK is partly res-
ponsible for islet cell death in response to cytokines, an effect that
appears not to involve NO production.
Insulin secretion in response to 16.7 mM glucose was severely
decreased after cytokine exposure, and no significant difference
between the FRK/RAK +/+ or −/− islets was observed
(Table 1). Similarly, cytokine-induced NO production was equal
in the FRK/RAK +/+ and −/− islets. Thus the results suggest
that FRK/RAK participates in an NO-independent manner in cyto-
kine-induced islet cell death without influencing the suppression
of insulin release.
FRK/RAK RNAi inhibits cytokine-induced islet cell death
The RNAi procedure has been used to silence gene expression
in insulin-producing cell lines [21,22]. When MIN6 (mouse
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Table 1 Insulin secretion, insulin content, NO production and DNA content of FRK/RAK +/+ and −/− islets in response to cytokine exposure for 18 h
Values are means +− S.E.M. for the number of observations given in parentheses.
Insulin secretion
1.7 mM glucose 16.7 mM glucose Insulin content NO production Islet DNA
(ng/10 islets) (ng/10 islets) (ng/30 islets) [µmol · (25 islets)−1 · (18 h)−1] (ng/30 islets)
FRK/RAK +/+ 4.2 +− 0.8 (6) 39 +− 8.0 (6) 448 +− 62 (6) 0.4 +− 0.1 (7) 672 +− 67 (4)
FRK/RAK +/+ 75 units/ml IL-1β + 1500 units/ml IFN-γ 8.3 +− 2.2 (6) 17 +− 5.9 (6) 360 +− 60 (6) 1.4 +− 0.9 (7) 552 +− 96 (4)
FRK/RAK −/− 3.8 +− 0.9 (6) 46 +− 4.6 (6) 663 +− 155 (6) 0.4 +− 0.1 (7) 610 +− 148 (4)
FRK/RAK −/− 75 units/ml IL-1β + 1500 units/ml IFN-γ 4.8 +− 1.0 (6) 6.6 +− 1.2 (6) 419 +− 94 (6) 1.3 +− 0.2 (7) 568 +− 132 (4)
insulinoma 6) or INS1 (insulinoma 1) insulin receptor, insulin-like
growth factor-1 receptor or the plasma membrane-related Ca2+-
ATPase-1 gene expression were assessed, the decrease was 91,
84 and 65–86% respectively. To assess the efficacy of RNAi
silencing with respect to the decrease in FRK/RAK protein
levels in our system, FRK/RAK-overexpressing RINm5F cells
were transfected with siRNA against FRK/RAK (Figure 4A).
This experiment was performed in RINm5F cells overexpressing
FRK/RAK since FRK/RAK could not be detected by Western-
blot analysis in isolated islets. FRK/RAK levels were reduced
by 62 +− 4.4% (n = 3) using this procedure. The simultaneous
transfection efficiency measured by uptake of a fluorescently
labelled oligonucleotide was 57 +− 4% (n = 3). Probing the blot
for c-Abl, c-Src and p42-p44 ERK revealed no effects of the
FRK/RAK siRNA on the expression of these kinases. Next,
the siRNA transfection efficiency in isolated mouse islets was
assessed, since transfection of intact islets could be less efficient
than that of RINm5F cells. Freshly isolated NMRI mouse islets
were immediately transfected with a scrambled oligonucleotide
containing a fluorescent tag, and on the next day, fluorescent cells
were analysed by FACS after cell trypsinization (Figure 4B). The
islets transfected with the fluorescent oligonucleotide displayed
an R2 population that suggests, after subtracting the corres-
ponding R2 value of the control cells, a transfection efficiency
of 26%. This value is significantly higher than that anticipated
for the corresponding DNA transfection, but agrees well with
the general notion that siRNA is more efficiently transfected
compared with DNA.
Finally, freshly isolated islets were transfected with siRNA
against FRK/RAK, and cytokine-induced cell death was deter-
mined 2 days later (Figure 4C). Cytokine-induced islet cell death
was significantly reduced after transfection with siRNA for
FRK/RAK.
Inhibition of FRK/RAK kinase activity by tyrosine kinase inhibitors
To determine the characteristics of FRK/RAK autokinase activity,
in vitro kinase reactions were performed on baculovirus-produced
FRK/RAK. Different known tyrosine kinase inhibitors were
added at three concentrations each, after which FRK/RAK
autophosphorylation was determined. Approximate IC50 values
for the inhibition of kinase activity were calculated and are shown
in Table 2. Most inhibitors were not effective in inhibiting FRK/
RAK. However, a few inhibitors show a profile of inhibition of
FRK/RAK that is comparable with the known target tyrosine
kinases (also listed in Table 1) of the corresponding inhibitors.
Those that inhibited FRK/RAK kinase activity with a potency
comparable with the reported inhibitory property were AG30
[IC50 FRK/RAK = 0.1 mM, IC50 EGFR (epidermal growth factor
receptor) = 0.1 mM], AG1024 (IC50 FRK/RAK = 15 µM, IC50 in-
sulin R = 10 µM), AG1872 (IC50 FRK/RAK = 200 nM, IC50
Figure 4 FRK/RAK knockdown by siRNA
(A) FRK/RAK protein expression after transfection of FRK/RAK-overexpressing RINm5F cells
with siRNA against murine FRK/RAK. Scrambled (Scr) oligonucleotide control transfection is
shown. The blot was also probed for c-Abl, c-SRC and p42-p44 ERK to assess loading. (B) Islet
transfection efficiency. Freshly isolated islets were transfected with a fluorescently scrambled
siRNA oligonucleotide. On the next day, the islets were dispersed and analysed by FACS.
A population of cells with increased fluorescence is indicated by R2. R1 indicates the viable
untransfected cell population. (C) Islet cell viability with or without cytokine addition (50 units/ml
IL-1β + 1000 units/ml IFN-γ ) after transfection with murine FRK/RAK RNAi. Results are the
means +− S.E.M. for three independent experiments. *P < 0.05 with a paired Student’s t test.
SRC = 100 nM), PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)
pyrazolo[3,4-d]pyrimidine) (IC50 FRK/RAK = 20 nM, IC50
SRC = 5 nM), SU4984 (IC50 FRK/RAK = 15 µM, IC50 fibroblast
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Table 2 Characteristics of FRK/RAK autokinase properties in response to
different inhibitors of tyrosine kinases
FGFR, fibroblast growth factor receptor; JAK2, Janus kinase 2; VEGFR, vascular endothelial
growth factor receptor.
Mouse FRK/RAK IC50 Reported inhibitory
(autokinase activity) property (IC50) Reference
AG30 0.1 mM EGFR = 0.1 mM [31,32]
AG370 > 50 nM PDGFR = 50 nM [33]
AG490 0.1 mM JAK2 = 100 nM [34,35]
AG879 > 30 µM TrkA = 10 µM [36]
AG957 > 3 µM Bcr-Abl = 1 µM [37,38]
AG1024 15 µM Insulin R = 10 µM [39]
AG1295 > 2 µM PDGFR = 1 µM [40,41]
AG1296 0.1 mM PDGFR = 0.5 µM [42]
AG1478 > 10 nM EGFR = 10 nM [43,44]
AG1872 (PP1) 0.2 µM SRC = 0.1 µM [45]
Genistein 10 mM EGFR = 20 µM [46]
PP2 20 nM SRC = 5 nM [45,47]
SU1498 > 3 mM VEGFR-2 = 0.7 µM [48,49]
SU4984 15 µM FGFR-1 = 10 µM [50]
D-65495 0.1 µM PDGFR = 0.1 µM [14]
D-68129 0.1 µM PDGFR = 0.1 µM [14]
growth factor receptor 1 = 10 µM), D-65495 [IC50 FRK/
RAK = 100 nM, IC50 PDGFR (platelet-derived growth factor
receptor) = 100 nM] and D-68129 (IC50 FRK/RAK = 100 nM,
IC50 PDGFR = 100 nM). Thus a number of tyrosine kinase
inhibitors have been identified that will inhibit FRK/RAK.
Effects of FRK/RAK kinase inhibitors on cytokine-induced
islet cell cytotoxicity
Among the identified tyrosine kinase inhibitors that would
relatively potently inhibit FRK/RAK, AG1024 was considered
unsuitable for further studies, since the insulin receptor has been
shown to be essential for β-cell function [23]. When testing the
others, the known SRC family inhibitors AG1872 and PP2, as
well as the EGFR inhibitor AG30, were found to aggravate islet
cell death under basal conditions and in response to cytokines
(results not shown). However, D-65495 and SU4984 consistently
inhibited cytokine-induced islet cell death in a dose-dependent
manner (Figures 5A and 5B). This inhibitory effect occurred
without concomitant effects on insulin secretion or NO production
(results not shown). Thus certain inhibitors of FRK/RAK activity
also counteract cytokine-induced islet cell death.
DISCUSSION
The aim of the present study was to assess to what extent the
cytoplasmic tyrosine kinase FRK/RAK participates in cytokine-
induced β-cell destruction. In a previous study, in which kinase-
active FRK/RAK (also named GTK/Bsk/IYK) was expressed
in β-cells in a transgenic mouse, increased susceptibility to
cytokines with respect to β-cell death was observed [12]. For
this reason, we proposed that FRK/RAK was a signalling
component that participates in β-cell destruction in Type I
diabetes. This disease is characterized by an early infiltration
of tissue macrophages in the vicinity of islets [2]. The cause of
macrophage infiltration has not been established, but it could be
the consequence of an early insult to the β-cell that initiates
an inflammatory reaction. The macrophages synthesize and
release inflammatory cytokines, such as IL-1β, IFN-γ and tumour
necrosis factor α [3]. These cytokines are known to cause β-cell
Figure 5 Dose–response of (A) D-65495 and (B) SU 4984 with respect to
islet cell viability
(A) Control islets were incubated with IL-1β (50 units/ml) + IFN-γ (1000 units/ml) for 18 h.
D-65495 was added 30 min before cytokines in some groups at different concentrations. Islet cell
viability was determined, and results are expressed as percentage death in relation to cytokine
addition alone. (B) The same conditions as in (A) were used. Results are the means +− S.E.M.
for 4–8 independent measurements. *P < 0.05, **P < 0.01 and ***P < 0.001 respectively for
a paired Student’s t test.
necrosis and apoptosis [4] and this effect is partly mediated by
NO production [24,25]. However, an NO-independent pathway
for cytokine-induced β-cell death has also been suggested [26].
Further destruction of β-cells at this stage will probably aggravate
and perpetuate the progression of disease, and eventually, the
inflammation reaches a level of intensity that causes massive
β-cell destruction after the activation of infiltrating cytotoxic T
lymphocytes [5]. The duration of this process in humans may
extend over several years. Any intervention that disrupts this
vicious cycle of β-cell destruction and activation of the immune
response may prevent the progression of disease.
Our current results with the FRK/RAK knockout mouse islets
confirm our notion that FRK/RAK is a tyrosine kinase involved
in β-cell destruction in response to cytotoxic cytokines. In
addition, this effect appears not to involve NO production and,
consequently, does not cause suppression of insulin secretion
in response to the cytokines. Thus cytokines appear to signal
through two pathways, one involving nuclear factor κB and NO
production, and a second occurring via FRK/RAK. Whereas the
former causes both suppression of insulin secretion and β-cell
death, the latter only exerts cytotoxic effects.
Despite numerous attempts, we have not been able to chara-
cterize the conditions that regulate FRK/RAK kinase activity.
Analogy with other SRC family members would suggest that
FRK/RAK is activated by its binding to other proteins via its SH2
(Src homology 2) or SH3 domains [27]. So far, we have only
identified one protein that associates with FRK/RAK and this is
the SHB (SH2 protein in β-cells) adapter protein [20]. Curiously,
SHB overexpression also causes enhanced cytokine-induced islet
cell death [28] and, thus, the FRK/RAK–SHB signalling complex
c© 2004 Biochemical Society
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may be a key sensor of cytotoxic signals in β-cells. Events
downstream of this complex in the cytotoxic pathway are so far
unknown.
In addition to regulation of FRK/RAK kinase activity by
association with signalling partners, Tyr-497 and Tyr-504 play a
role in regulating the activity and properties of FRK/RAK [10,11].
In the present study, we show that these tyrosine residues are
not autophosphorylation sites of FRK/RAK by two-dimensional
phosphopeptide mapping. Instead, the results are compatible
with the view that the major autophosphorylation site is Tyr-
394, which by analogy with SRC is a positive regulator of
kinase activity. FRK/RAK produced in Sf9 insect cells displays
similar kinase activity irrespective of whether Tyr-497 and Tyr-
504 are mutated or not. In contrast, when FRK/RAK-Y504F is
expressed in RINm5F cells, its kinase activity is increased. Thus
this residue does not become phosphorylated in the Sf9 cells
and, consequently, fails to exert negative regulation of kinase
activity unlike in the RINm5F cells. The kinase(s) responsible for
phosphorylation of Tyr-497 and Tyr-504 in FRK/RAK remain(s)
elusive. The Y497/504F double mutant exhibited decreased
kinase activity in the Sf9 cells, suggesting a structural perturbation
of FRK/RAK in this case.
Our screening of the known tyrosine kinase inhibitors revealed
several chemical compounds that cause inhibition of FRK/RAK
activity with relatively high specificity. Two were known
inhibitors of SRC family of kinases and the others were inhibitors
of receptor tyrosine kinases. When FRK/RAK was originally
cloned, it was noted that in the kinase domain VI, FRK/RAK
has the sequence DLAARN, which is conserved among tyrosine
kinase receptors. Such a structural relationship may explain
the finding that receptor tyrosine kinase inhibitors also inhibit
FRK/RAK activity. Of the inhibitors tested, only SU4984 and
D-65495 consistently inhibited cytokine-induced islet cell death.
The others either aggravated the toxic response or had no effect.
Particularly, the SRC family inhibitors were noxious to the islet
cells. Thus it appears that inhibition of other kinases in islet cells,
particularly SRC family members other than FRK/RAK, will
exacerbate the toxic response. The failure of D-68129 to prevent
the toxic response to cytokines at first appeared intriguing,
since its inhibitory profile is very similar to that of D-65495.
However, D-68129 is less soluble compared with D-65495 and
this difference may explain the lower potency in cell culture.
The results obtained with the inhibitors do not exclude the
possibility that a part of their effect relates to inhibition of
tyrosine kinases other than FRK/RAK. This may be particularly
true for SU4984, which decreased islet cell death to a larger
extent than what was seen in the FRK/RAK knockout islets.
However, contribution of FRK/RAK to this inhibitory effect
is quite probable. The relatively non-specific tyrosine kinase
inhibitors genistein, herbimycin A and tyrphostin have all been
shown previously to reduce cytokine-induced nitrite formation
and iNOS (inducible nitric oxide synthase) gene expression, but
their effects on islet cell viability have not been investigated
[29,30].
Taken as a whole, our study suggests that FRK/RAK plays a
role in cytokine-induced islet cell death and specific inhibition of
this kinase may alleviate the toxic response to cytokines. Finding a
specific inhibitor of FRK/RAK that could be administered in vivo
would thus provide the pharmacological means to intervene in
the progression of Type I diabetes. The FRK/RAK knockout
indicates that this gene is not essential for mouse viability.
Thus pharmacological intervention under early phases of the
development/progression of disease, which reduces β-cell death,
could have an impact on the ensuing immune response in such a
manner that disease progression is halted.
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